GHRH (Growth Hormone Releasing Hormone) Peptide

Growth Hormone Releasing Hormone is commonly referred to as GRF (Growth Hormone Releasing Factor) or GHRH 1-44 because it is a peptide of 44 amino acids. Research studies have shown that in most species GRF (1-44) stimulates the release and synthesis of growth hormone. GRF is synthesized by neurons in the arcuate nucleus of the hypothalamus. After being released into the pituitary portal circulation, it stimulates GH release by the somatotrophs in the pituitary gland. Endogenous GHRH (1-44) has a very short active life, but is released from the hypothalamus before traveling a very short distance to the anterior pituitary, where GH is released. In contrast, exogenous peptides are typically supplied exogenously through one of several types of injection, and must circulate prior to reaching the pituitary and activating the GH-storing-and-releasing cells called somatotrophs. Research studies have shown that GHRH helps stimulate the release and synthesis of growth hormone. Research has also shown that It helps promotes slow-wave sleep. GHRH is synthesized by neurons in the arcuate nucleus of the hypothalamus. GHRH stimulates GH production and release by binding to the GHRH Receptor GRFR on cells.

 

GHRH Peptide Analogues: CJC-1295, Mod GRF, Sermorelin

CJC-1295 - also known as CJC1295 DAC and MPA-Lys30, D-Ala2, Gln8, Ala15, Leu27-GRF amide:

CJC-1295 DAC, a tetrasubstituted analog of GRF 1-29, has a D-Ala at the 2-position, a Gln at the 8-position to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, an Ala at position 15 to enhance bioactivity, and a Leu at position 27 to prevent methionine oxidation along with the MPA-Lys at the C terminus. CJC-1295 is a maleimido derivative of GRF 1-29, which is modified in such a way that it has the ability to bioconjugate with serum albumin, thus increasing its half-life and possible therapeutic window.

Modified GRF 1-29 - also known as D-Ala2, Gln8, Ala15, Leu27-GRF amide:

Modified GRF 1-29 is a tetrasubstituted analog of GRF 1-29 that has a D-Ala at the 2-position, a Gln at the 8-position to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, an Ala at position 15 to enhance bioactivity, and a Leu at position 27 to prevent methionine oxidation. Mod GRF 1-29 is modified in such a way that increasing its half-life and possible therapeutic window, but in a more natural pulsatile manner similar to GRF 1-44.

Sermorelin - also known as GRF 1-29 and GRF 1-29 Amide:

Sermorelin is a growth hormone releasing hormone analogue which is a 29-amino acid polypeptide representing the 1-29 fragment from endogenous human growth hormone releasing hormone, and is thought to be the shortest fully functional fragment of GHRH.